Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors

Unresectable or metastatic gastrointestinal stromal tumors fail to respond to conventional chemotherapy and are usually fatal within 12 to 18 months. Most gastrointestinal stromal tumors have a defect in KIT, a transmembrane tyrosine kinase receptor. The abnormality prevents the death of the cell an...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2002-08, Vol.347 (7), p.472-480
Hauptverfasser:	Demetri, George D, von Mehren, Margaret, Blanke, Charles D, Van den Abbeele, Annick D, Eisenberg, Burton, Roberts, Peter J, Heinrich, Michael C, Tuveson, David A, Singer, Samuel, Janicek, Milos, Fletcher, Christopher D.M, Fletcher, Jonathan A, Silverman, Stuart G, Silberman, Sandra L, Capdeville, Renaud, Kiese, Beate, Peng, Bin, Dimitrijevic, Sasa, Druker, Brian J, Corless, Christopher, Joensuu, Heikki
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Aged, 80 and over Antineoplastic Agents - adverse effects Antineoplastic Agents - pharmacokinetics Antineoplastic Agents - therapeutic use Benzamides Biological and medical sciences Female Gastroenterology. Liver. Pancreas. Abdomen Gastrointestinal Neoplasms - drug therapy Gastrointestinal Neoplasms - pathology Humans Imatinib Mesylate Kinases Leukemia Male Medical sciences Middle Aged Piperazines - adverse effects Piperazines - pharmacokinetics Piperazines - therapeutic use Protein-Tyrosine Kinases - antagonists & inhibitors Proteins Proto-Oncogene Proteins c-kit - genetics Pyrimidines - adverse effects Pyrimidines - pharmacokinetics Pyrimidines - therapeutic use Radiation therapy Remission Induction Signal Transduction - drug effects Stomach. Duodenum. Small intestine. Colon. Rectum. Anus Stromal Cells - pathology Survival Analysis Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!